Gilead Sciences (NASDAQ:GILD) Stock: Insider Daniel Patrick O’day Sells 15,881 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel O’Day sold 15,881 shares of the firm’s stock in a transaction on Friday, October 30th. The stock was sold at an average price of $175.25, for a total value of $2,783,145.25. Following the completion of the sale, the chief executive officer directly owned 566,683 shares of the company’s stock, valued at $99,311,195.75. The trade was a 2.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Monday, November 2nd, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $169.74, for a total value of $2,546,100.00.
• On Thursday, October 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $147.90, for a total transaction of $2,218,500.00.
• On Tuesday, September 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $148.64, for a total transaction of $2,229,600.00.

Gilead Sciences Trading Down 0.2%

Shares of GILD stock traded down $0.35 during mid-day trading on Monday, reaching $170.33. The stock had a trading volume of 8,856,542 shares, compared to its average volume of 5,751,038. Gilead Sciences, Inc. has a 1-year low of $116.88 and a 1-year high of $175.65. The business’s fifty day moving average is $151.36 and its 200-day moving average is $140.03. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.19 by $0.36. The business had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the business posted $2.47 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post -1.03 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is currently -103.80%.

Institutional Investors Weigh In On Gilead Sciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Alta Advisers Ltd boosted its position in shares of Gilead Sciences by 80.2% during the third quarter. Alta Advisers Ltd now owns 8,997 shares of the biopharmaceutical company’s stock worth $1,341,000 after buying an additional 4,005 shares during the period. Syverson Strege & Co raised its holdings in shares of Gilead Sciences by 6.9% in the 3rd quarter. Syverson Strege & Co now owns 3,570 shares of the biopharmaceutical company’s stock valued at $532,000 after buying an additional 229 shares during the period. Principle Wealth Partners LLC raised its holdings in shares of Gilead Sciences by 15.7% in the 3rd quarter. Principle Wealth Partners LLC now owns 2,788 shares of the biopharmaceutical company’s stock valued at $416,000 after buying an additional 378 shares during the period. REAP Financial Group LLC lifted its stake in Gilead Sciences by 11.4% during the 3rd quarter. REAP Financial Group LLC now owns 1,380 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 141 shares in the last quarter. Finally, Telos Capital Management Inc. acquired a new position in Gilead Sciences during the 3rd quarter worth about $215,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead said it will present late-breaking clinical data and real-world evidence from more than 50 studies at HIV Glasgow 2026 on November 8–11. Updates on HIV therapies, its development pipeline and strategic collaborations could provide catalysts if the results reinforce the company’s leadership in HIV treatment. Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
• Positive Sentiment: Analysts have raised several Gilead price targets, including targets of $175, $181, $183, $188, $190 and $200. Separately, an updated fair-value estimate rose from $158.65 to $165.31, reflecting improved views of third-quarter execution, the HIV business and pipeline assets. Gilead Sciences Price Target Raised to $200.00 Gilead Stock Fair Value Edges Higher After Analyst Target Increases
• Positive Sentiment: Gilead continues to receive favorable analyst attention, including a Morgan Stanley Buy rating and inclusion among healthcare stocks described as having Strong Buy ratings and high quantitative scores. Gilead Sciences Receives a Buy from Morgan Stanley
• Neutral Sentiment: Former Gilead U.S. Medical Affairs head Dean Hakanson joined GOA Therapeutics as chief medical officer. The move highlights executive experience gained at Gilead, but it does not directly change Gilead’s operations or financial outlook. Former Gilead Head of U.S. Medical Affairs Joins GOA Therapeutics
• Negative Sentiment: One recent earnings analysis characterized Gilead’s outlook as mixed: revenue guidance was raised, but the EPS outlook worsened. That contrast could limit upside by raising concerns about profitability even as the HIV business remains strong. Gilead Sciences Q3 2026 Earnings Analysis

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GILD. Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday. BMO Capital Markets reissued an “outperform” rating and set a $184.00 price target on shares of Gilead Sciences in a research report on Friday. Finally, Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $169.74.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.